-
Metastatic Castration-Resistant Prostate Cancer Market to Register Stupendous Growth During the Study Period (2020–2034) Owing to the Active Participation of Pharma Companies | DelveInsight
17 Feb 2025 18:00 GMT
… cases of Prostate cancer
Age-specific cases of Prostate cancer
Total cases of Prostate cancer by … (PF-06821497): Pfizer
CABOMETYX (cabozantinib, XL184): Exelixis and Ipsen Pharma
Masitinib …
-
Metastatic Castration-Resistant Prostate Cancer Market to See Unprecedented Growth by 2034 | DelveInsight
05 Feb 2025 13:08 GMT
… ), Mevrometostat (PF-06821497), CABOMETYX (cabozantinib, XL184), TRUQAP (capivasertib, AZD5363), Masitinib, 177Lu … cases of Prostate cancer
• Age-specific cases of Prostate cancer
• Total cases of Prostate cancer by …
-
Ipsen provides update on CONTACT-02 Phase III trial in metastatic castration-resistant prostate cancer following final overall survival analysis
15 Sep 2024 12:45 GMT
… in metastatic castration-resistant prostate cancer (mCRPC). The … With Metastatic Castration-Resistant Prostate Cancer (mCRPC): Primary … et al., Cabozantinib (XL184), a novel MET and … 47;prostate-cancer-statistics/. Accessed August 2024
7 Prostate Cancer: …
-
eTMF As A Factory: Elements For High-Volume, High-Quality Processing
25 Mar 2025 11:13 GMT
… Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously …
-
Ipsen communique de nouvelles données sur l’essai de Phase III CONTACT-02 dans le cancer de la prostate métastatique résistant à la castration au terme de l’analyse finale de la survie globale
15 Sep 2024 12:45 GMT
… With Metastatic Castration-Resistant Prostate Cancer (mCRPC): Primary … et al., Cabozantinib (XL184), a novel MET and … 47;prostate-cancer-statistics/. Accessed August 2024
7 Prostate Cancer: … in Castration-Resistant Prostate Cancer: Results From SEARCH …
-
Cabozantinib s-malate by Exelixis for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
22 Dec 2023 06:00 GMT
… -malate overview
Cabozantinib s-malate (XL184, BMS907351, Cometriq) is a s … cervical cancer, metastatic castration-resistant prostate cancer (mCRPC), clear cell renal cell …
-
Exelixis Announces Dose-Escalation Results from the Phase 1 STELLAR-001 Trial Evaluating XL092 Alone and in Combination with an Immune Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ESMO 2022
10 Sep 2022 07:37 GMT
… carcinoma (RCC), metastatic castration-resistant prostate cancer (CRPC) and breast cancer. The … in phase 1 (trial identifier: XL184-011): XL092 demonstrated a 71% …
-
Exelixis Announces Dose-Escalation Results from the Phase 1 STELLAR-001 Trial Evaluating XL092 Alone and in Combination with an Immune Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ESMO 2022
10 Sep 2022 07:39 GMT
… carcinoma (RCC), metastatic castration-resistant prostate cancer (CRPC) and breast cancer. The … in phase 1 (trial identifier: XL184-011): XL092 demonstrated a 71% …
About
© 1995-2025